The Clinical Curative Effect Observation Of PEG-IFNa-2a And Entecavir In The Treatment Of Chronic Hepatitis B Patients With Positive HBeAg

Objective:The analyze of the application of PEG-IFNα-2a and entecavir in thetreatment of HBeAg positive chronic hepatitis B patients,through theobservation of HBsAg, HBeAg and HBVDNA quantitative, ALTlevel,respectivelyPEG-IFN α-2a and entecavir at the treatment of12weeks,24weeks,48weeks and HBeAg serological conversion,HBVDNA negative conversion rate, the recover rate of ALT at48weeksand adverse effect during the course of treatment,to explore the clinicalcurative effect and drug safety of PEG-IFNa-2a and entecavir.Methods:The cases from November2012to October2014in the secondhospital of Jilin university,receiving PEG-IFN α-2a and entecavirantiviral treatment among HBeAg positive chronic hepatitis B patients.All the cases are in accordance with the diagnostic criterial of 《thechronic hepatitis B prevention guide》in2010,exclusion of HAV,HIV,HCV, and HDV infection and the patients who have a combination ofalcoholic liver disease, non-alcoholic fatty liver disease,drug-inducedliver injury，autoimmune liver disease, liver cirrhosis or liver cancer withHBV infection.All the cases are divided into two groups,PEG-IFNα-2a group have 34people, Entecavir group have31people.PEG-IFNα-2a group:180ugvia subcutaneous injection, once a week;Entecavir group:0.5mg for oraladministration once a day.A course of48weeks of the two groups,but thePEG-IFNα-2a group have4people quit treating.To observe the HBsAg,HBeAg and HBVDNA quantitative, ALT level,respectivelyPEG-IFNa-2a and entecavir at the treatment of12weeks,24weeks and48weeks and HBeAg serological conversion, HBVDNA negativeconversion rate, the recover rate of ALT at48weeks and adverse effectduring the course of treatment.Results:(1)PEG-IFNa-2a group and entecavir group HBeAg quantitativecomparison at12,24,48weeks,the difference is statistically significant(P<0.05), and PEG-IFNa-2a group decreases obviously;Through the12weeks,24weeks and48weeks quantitative value contrast, HBsAg in12weeks is no statistical difference (P＜0.05), and at24,48weeks, thedifference is statistically significant (P <0.05), and PEG-IFNa-2a groupdecreases obviously.(2) In the treatment of48weeks, PEG-IFNa-2a group has a higherHBeAg serological conversion rate than entecavir group,statisticallysignificant (P <0.05).(3)The treatment for12weeks and24weeks and48weeks, with thecomparison of PEG-IFNa-2a group and entecavir HBVDNA level,thedifference is statistically significant (P <0.05), and entecavir groupdecreases obviously.At48weeks, entecavir group has higher HBVDNA negative transformation rate,the difference is statistically significant.(4).Treatment for12weeks and24weeks and48weeks, there are nostatistically significant difference (P>0.05) with the contrast of PEG-IFNa-2a and entecavir group ALT level.Conclusion:The process of applying PEG-IFNa-2a and entecavir to treat chronichepatitis B patients with positive HBsAg.HBeAg quantitative detectioncan be used earlier than HBsAg quantitative detection to judge thecurative effect. PEG-IFNa-2a is superior to entecavir in serologicalresponse.In respect of virological response, entecavir is better than that ofPEG-IFNa-2a, and has higher drug safety.Two groups of patients have noobvious difference in biochemical responses.